Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC

Ansary, Mervat El; Mogawer, Sherif; Elhamid, Samah Abd; Alwakil, Sahr; Aboelkasem, Fatma; Sabaawy, Hatem E.; Abdelhalim, Olfat

doi:10.1007/s00432-012-1298-8

Cited by 88 publications

(63 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, chronic infection, necrosis and cell regeneration, fibrosis and cirrhosis are, together with the direct mechanisms, the high risk factors for HCC. Finally, HBV or HCV chronic infection has immunomodulatory and immunosuppressive effects [71][72][73] .…”

Section: Development Of Hcc In Chronic Hcv Infectionmentioning

confidence: 99%

Hepatocellular carcinoma and the risk of occupational exposure

Rapisarda

Loreto

Malaguarnera

et al. 2016

WJH

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. The main risk factors for HCC are alcoholism, hepatitis B virus, hepatitis C virus, nonalcoholic steatohepatitis, obesity, type 2 diabetes, cirrhosis, aflatoxin, hemochromatosis, Wilson's disease and hemophilia. Occupational exposure to chemicals is another risk factor for HCC. Often the relationship between occupational risk and HCC is unclear and the reports are fragmented and inconsistent. This review aims to summarize the current knowledge regarding the association of infective and non-infective occupational risk exposure and HCC in order to encourage further research and draw attention to this global occupational public health problem. Core tip: Hepatocellular carcinoma (HCC) is the fifth most common human cancer. This review summarizes current knowledge regarding the occupational risk factors of HCC. In particular, we underline not only the infective but also non-infective occupational risk exposure, including chemical agents and toxic metabolites which are a major cause of liver damage.

show abstract

Section: Development Of Hcc In Chronic Hcv Infectionmentioning

confidence: 99%

Hepatocellular carcinoma and the risk of occupational exposure

Rapisarda

Loreto

Malaguarnera

et al. 2016

WJH

View full text Add to dashboard Cite

show abstract

“…In the present study, HepG2 cells were used for T cell cytotoxicity analysis. Although the HepG2 cell line has been demonstrated to be misidentified and be derived from hepatoblastoma instead of hepatocellular carcinoma (25), the use of HepG2 cells as a model of target cells derived from tumor tissues is suitable for cytotoxicity analysis of immune cells cultured in vitro (26)(27)(28). Among the four groups (Fig.…”

Section: Discussionmentioning

confidence: 99%

The effects of hemocyanin on T cells cultured inï¿½vitro

Liu

Chen

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. As a broad-spectrum antibiotic, gentamicin is used extensively in T cell culturing in vitro, but preliminary studies have identified that T cell activity is significantly affected by gentamicin. In the present study, the hemocyanin from Litopenaeus vannamei (L. vannamei) was selected as an additive for T cell cultures in vitro. Compared with those in the control group, the cell quantity exhibited no significant difference, and the formation rate of cell colony increased gradually with increases in the hemocyanin concentration. Additionally, flow cytometry assays identified that cluster of differentiation (CD)3 + CD4 + and CD4 + CD25 + T cells in the 0.2 µg/ml hemocyanin (Hem 3) group were all significantly increased. Furthermore, cell cycle analysis demonstrated that T cells in the G0/G1 phase were significantly decreased in the Hem 3 group compared with in the control, 0.05 µg/ml (Hem 1) and 0.1 µg/ml (Hem 2) groups, and cells in the S phase were significantly elevated in the Hem 3 group compared with in the control and Hem 1 groups. In addition, MTT analysis indicated that the cytotoxicity of T cells towards HepG2 cells was significantly increased in the Hem 3 group compared with in the control, Hem 1 and Hem 2 groups. Taken together, the present study identified that hemocyanin may improve the proliferation and cytotoxicity of T cells, and the results supported the use of hemocyanin in T cell adoptive immunotherapy.

show abstract

“…Notably, a monthly boost vaccination resulted in a significantly better 1 year survival [74] . In another RCT on advanced HCC, DCs pulsed with HepG2 cell lysate resulted in 13.3% patients with PR and 60% with SD after 6 mo of treatment [75] . However, the proportion of clinical response with this therapy is relatively low.…”

Section: Tumor Vaccine Using Antigen-presenting Cellsmentioning

confidence: 97%

Immunotherapy for hepatocellular carcinoma: From basic research to clinical use

Hong

Prasoon

et al. 2015

WJH

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common cancer worldwide with a poor prognosis. Few strategies have been proven efficient in HCC treatment, particularly for those patients not indicated for curative resection or transplantation. Immunotherapy has been developed for decades for cancer control and is attaining more attention as a result of encouraging outcomes of new strategies such as chimeric antigen receptor T cells and immune checkpoint blockade. Right at the front of the new era of immunotherapy, we review the immunotherapy in HCC treatment, from basic research to clinical trials, covering anything from immunomodulators, tumor vaccines and adoptive immunotherapy. The mechanisms, efficacy and safety as well as the approach particulars are unveiled to assist readers to gain a concise but extensive understanding of immunotherapy of HCC.

show abstract

Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC

Cited by 88 publications

References 21 publications

Hepatocellular carcinoma and the risk of occupational exposure

Hepatocellular carcinoma and the risk of occupational exposure

The effects of hemocyanin on T cells cultured inï¿½vitro

Immunotherapy for hepatocellular carcinoma: From basic research to clinical use

Contact Info

Product

Resources

About